Now showing items 1-5 of 5

  • Characteristics of and differences between Pasifika women and New Zealand European women diagnosed with breast cancer in New Zealand

    Brown, Charis; Lao, Chunhuan; Lawrenson, Ross; Tin Tin, Sandar; Schaaf, Michelle; Kidd, Jacquie; Allan-Moetaua, Anne; Herman, Josephine; Raamsroop, Reena; Campbell, Ian; Elwood, Mark (2017)
    AIM: Breast cancer in New Zealand-based Pasifika women is a significant issue. Although Pasifika women have a lower incidence of breast cancer compared to New Zealand European women, they have higher breast cancer mortality ...
  • The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer

    Lao, Chunhuan; Edlin, Richard; Rouse, Paul; Brown, Charis; Holmes, Michael; Gilling, Peter; Lawrenson, Ross (BioMed Central, 2017)
    Background: Radical prostatectomy is the most common treatment for localised prostate cancer in New Zealand. Active surveillance was introduced to prevent overtreatment and reduce costs while preserving the option of radical ...
  • Mortality in the Waikato Hospital Systemic Sclerosis Cohort

    Ooi, Clement; Solanki, Kamal; Lao, Chunhuan; Frampton, Chris; White, Douglas (Wiley, 2017)
    Objective To characterize the causes of mortality and standardised mortality ratio in a cohort of patients with systemic sclerosis (SSc). Methods A cohort of 132 patients enrolled at the Waikato Systemic Sclerosis ...
  • Urban Rural Differences in Breast Cancer in New Zealand

    Lawrenson, Ross; Lao, Chunhuan; Elwood, Mark; Brown, Charis; Sarfati, Diana; Campbell, Ian (MDPI AG, 2016)
    Many rural communities have poor access to health services due to a combination of distance from specialist services and a relative shortage of general practitioners. Our aims were to compare the characteristics of urban ...
  • The use of trastuzumab in New Zealand women with breast cancer

    Lawrenson, Ross; Lao, Chunhuan; Campbell, Ian; Harvey, Vernon; Brown, Charis; Seneviratne, Sanjeewa; Edwards, Melissa; Elwood, Mark; Kuper-Hommel, Marion (Wiley, 2017)
    Aim Trastuzumab was first funded in New Zealand for use in HER2+ve stage I–III breast cancer in 2007. This observational study aims to ascertain the patterns of use of trastuzumab in women with invasive HER2+ve breast ...